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Introduction
Cholangiocarcinoma is a high mortal malignancy,1 in that most
patients present initially with unresectable disease, undergo pallia-
tive therapies, and die within 12 months.2 Given the small number
of available studies and lack of randomized trials, there is no estab-
lished role for neoadjuvant and adjuvant therapy associated with
cholangiocarcinoma.3 Systemic (radio-) chemotherapy applied in a
palliative setting has not been shown to prolong survival signifi-
cantly.4-6 At present, complete surgical resection with histologically
negative resection margins is the only cure for cholangiocarcinoma.
Cholangiocarcinoma is the second most common type of pri-
mary hepatic tumor,7,8 and accounts for 3% of all gastrointestinal
cancers.7 Among cholangiocarcinomas, 60-70% arise at the bifur-
cation of the hepatic ducts (Klatskin tumours), 20-30% in the distal
extrahepatic common bile duct, and 5-10% are peripheral, arising
within intrahepatic ducts of the liver parenchyma itself.9 Several
international studies have shown an increasing incidence and mor-
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Extrahepatic bile duct cancer is a high mortal malignancy. Angiopoietin (Ang) and its receptor Tie, which are known to contribute to
angiogenesis, have recently been reported to participate in the proliferation and differentiation of malignant tumor cells. The aim of this
study is to investigate the expression and the significance of Ang-1, 2 and Tie-2 in extrahepatic bile duct carcinoma cells. We used
immunohistochemistry to study 119 cases of surgically resected human extrahepatic bile duct carcinoma, and Reverse Transcription-
Polymerase Chain Reaction (RT-PCR) to confirm the expression of Ang-1, 2 and Tie-2 mRNA. Among these 119 cases, 52 (43.7%), 50
(42.0%) and 89 (74.8%) cases showed positive staining for Ang-1, 2 and Tie-2, respectively, in bile duct carcinoma cells. In 38 cases of normal
mucosa, 6 (15.8%), 10 (26.3%) and 9 (23.7%) cases were positive for Ang-1, 2 and Tie-2, respectively. The positivity for Ang-1 and Tie-2 in
normal mucosa was significantly different from all carcinomas (p<0.01 and p<0.001, respectively). We found no significant correlation between
Ang-1 and Ang-2 expression and other clinicopathological factors such as histological differentiation, grade of tumor invasion or survival rate
after surgery. In contrast, Tie-2 expression correlated significantly with degree of desmoplasia, cancer stage and survival of patients. RT-PCR
analyses of five surgically resected tumor samples and three human bile duct cancer cell lines all showed positive expression of Ang-1, 2 and
Tie-2 mRNAs. High expressions of Ang-1, 2 and Tie-2 in human extrahepatic bile duct carcinoma cells suggested that Ang-Tie system may be
involved in the progression of human bile duct cancer.
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tality rate for intrahepatic cholangiocarcinoma, and decreasing in-
cidence and mortality for extrahepatic bile duct carcinoma.8,10-12
Some risk factors for cholangiocarcinoma include primary sclerosing
cholangitis, liver fluke infestation, hepatolithiasis, and abnormali-
ties of biliary anatomy;13,14 however, not only the mechanism of the
carcinogenesis but also the biological aggressiveness of bile duct
carcinoma has not been fully elucidated.
Angiopoietin (Ang)-1 and Ang-2 function as ligands for Tie-2
vascular endothelial-specific receptor tyrosine kinase, and as such
are considered important growth factors during angiogenesis.15-19
Ang-1 acts as an agonist of Tie-2 receptor, stimulating Tie-2-
mediated stabilization and maturation of vessels by promoting in-
teractions between endothelial cells and supporting cells,20 as well
as by stimulating endothelial cell migration in vitro.17,19 In contrast,
Ang-2 is a context-dependent antagonist;18,19 by binding to Tie-2
with an affinity similar to that of Ang-1, it blocks Ang-1-stimulated
receptor phosphorylation in endothelial cells.18
Tie-2 is a receptor tyrosine kinase21 that is expressed at high levels
in embryos and plays a critical role in embryonic development.15,16,22,23
Experimental evidence from the targeted disruption of the Tie-2
gene suggests that Tie-2 plays a pivotal role in angiogenesis and
vascular remodeling during development.16 Extra-endothelial ex-
pression of Ang-1, 2 and Tie-2 has also been documented recently,
and increasing varieties of tumor cells, including gastric carcinoma
cells,24 colorectal carcinoma cells,25 gastrointestinal stromal tumor,26
and glioma cells27 have been reported to express Ang-1, 2 and Tie-2.28
Also, in primary murine tumors and their metastases, soluable form of
the extracellular domain of murine Tie-2 for Tie-2 inhibitor caused
antitumor effect by inhibiting the tumor angiogenesis.29,30 These re-
ports suggest that the Ang-Tie system may play a role in the pro-
gression of malignant tumors. To promote a better understanding
of the Ang-Tie system, the objective of this study was to evaluate




We studied 119 extrahepatic bile duct carcinomas, excluding
those involving the gall bladder or ampulla. Specimens from
Nagasaki University Hospital and the National Nagasaki Medical
Center were obtained from patients between 1993 and 2007. All
tumors were resected with clear or nearly clear margins. Cases
were staged according to the TNM classification of the UICC.31
Bile duct adenocarcinomas was divided histologically into papillary-
and tubular-type adenocarcinomas. Tubular-type adenocarcinomas
were further classified according to their degree of differentiation
(well, moderately or poorly differentiated). Examinations to iden-
tify lymphatic, venous and perineural invasions were performed on
routine slides. To identify venous invasions, Elastica van Gieson
staining was used in addition to hematoxylin and eosin. Invasions
identified certainly were defined as ''present'', whereas not observed
certainly were defined as ''absent''. Lymph node metastasis was de-
fined as ''present'' when histologically proven, whereas not ob-
served histologically were defined as ''absent''. Among the invasive
cases, we also classified the degree of desmoplastic stromal reac-
tion into ''scirrhous'' or ''non-scirrhous'', and tumor growth patterns
as ''non-infiltrative'' or ''infiltrative''. Two independent pathologists
(Y. Mihara and T. Nakayama) diagnosed all cases by examining
the whole stepwise section of each extrahepatic bile duct. Those of
questionable cases were omitted from the study.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissues were cut into 4
m sections, deparaffinized in xylene and rehydrated in phos-
phate-buffered saline. Deparaffinized sections were preincubated
with normal bovine serum to prevent nonspecific binding, and then
incubated overnight at 4oC with an optimal dilution (0.1 g/ml) of
polyclonal goat antibody against Ang-1 (C-19) and Ang-2 (N-18),
or polyclonal rabbit antibody against human Tie-2 (C-20) (all pur
chased from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
Slides reacted with Ang-1 and Ang-2 antibodies were then incu-
bated with biotinylated horse anti-goat immunoglobulin antibody;
and those with Tie-2 were incubated with biotinylated horse anti-
rabbit immunoglobulin antibody. Secondary antibody reaction prod-
ucts were viewed using diaminobenzidine (DAB; DAKO Ltd.,
Glostrup, Denmark). Primary antibodies pre-absorbed with excess
recombinant Ang-1, 2 or Tie-2, respectively (Santa Cruz Biotechnology,
Inc.), were used as negative controls. Proliferated capillaries
served as an internal positive control for Ang-1, 2 and Tie-2
immunostaining. Two independent investigators (Y. Mihara and T.
Nakayama) analyzed all immunohistochemical results. Degree of
Ang-1, 2 or Tie-2 expression was classified into two categories de-
pending on the percentage of cells stained: (-) for 0% to 10% posi-
tive cells; and (+) for more than 10% positive carcinoma cells.
Cell Culture
HuCCT1, HuH28 and OZ cell lines,32-34 derived from human bile
duct cancer, were obtained from the Human Health Resources
Bank (Osaka, Japan). All cell lines were maintained in RPMI 1640
(Invitrogen Corp., Carlsbad, CA, USA) supplemented with heat-
inactivated 10% fetal calf serum (Invitrogen Corp.) and 2 mM
glutamine (Invitrogen Corp.), and incubated at 37 ℃ in a humidi-
fied atmosphere containing 5% CO2.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Total RNA was prepared using the acid guanidine phenol method35
from five human bile duct carcinoma tissues and three human bile
duct cancer cell lines, HuCCT1, HuH28 and OZ.32-34 Cellular RNA
(1 g) was incubated at 37℃ for 1 hour in 50 l of reverse
transcriptase buffer containing 20 units of RNAsin (Promega Corp.,
Madison, WI), 100 pmol of random hexamer primers (Boehringer
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Mannheim, Mannheim, Germany), and 400 units of Moloney
murine leukemic virus reverse transcriptase (Invitrogen Corp.).
Reverse transcription was then terminated at 95℃ for 10 minutes,
and 20% of the resultant cDNA was removed for PCR. PCR tem-
plates were amplified using 50 pmol of each primer and 2.5 units
of Taq DNA polymerase. Primer sequences were as follows:
human Ang-1 5'-GGGGGAGGTTGGACTGTAAT-3' (sense) and
5'-AGGGCACATTTGCACATACA-3' (antisense), human Ang-2
5'-GGATCTGGGGAGAGAGGAAC-3' (sense) and 5'-CTCTGCA-
CCGAGTCATCGTA-3' (antisense), human Tie-2 5'-CTGCAGTG-
CAATGAAGCATGC-3' (sense) and 5'-CTGCAGACCCAAACTC-
CTGAG-3' (antisense), human -actin 5'-TCCTCCCTGGAGAAG-
ACTA-3' (sense) and 5'-AGTACTTGCGCTCAGGAGGA-3' (antisense).
Primer pairs were designed to span introns in their respective
human genes. Predicted amplification product sizes using these
primers pairs are 362 bp (Ang-1), 535 bp (Ang-2), 389 bp (Tie-2)
and 313 bp ( -actin). Samples were subjected to 30 cycles of PCR
amplification (denaturation at 94 ℃ for 1 minute, annealing at 60
℃ for 1 minute, and primer extension at 72 ℃ for 1.5 minutes) in
a thermocycler. Equivolume aliquots of amplification reactions
were resolved on 1.5% agarose gels, and DNA was visualized by
ethidium bromide staining.
Statistical analysis
Stat View II (Abacus Concepts, Inc., Berkeley, CA, USA) was
used for statistical analyses. Analyses comparing degrees of Ang-
1, 2 and Tie-2 expression applied Mann-Whitney's U test and Chi-
square for independent tests. Survival durations were calculated
using the Kaplan-Meier method. A log-rank test was used to com-
pare cumulative survival between patient groups. p<0.05 was con-
sidered significant for each analysis.
Results
Immunohistochemical staining of Ang-1, 2 and Tie-2
Immunohistochemical results from the bile duct carcinomas are
summarized in Tables 1, 2 and Figure 1. Among 119 cases, 52
(43.7%), 50 (42.0%) and 89 (74.8%) cases showed positive stain-
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Table 1. Immunohistochemical staining for Ang-1, 2 and Tie-2 and the relationships between clinicopathological findings. (119 cases)
Ang-1 Ang-2 Tie-2
n + - + - + -
** NS ***
Normal mucosa 38 6(15.8%) 32(84.2%) 10(26.3%) 28(73.7%) 9(23.7%) 29(76.3%)
Total carcinoma 119 52(43.7%) 67(56.3%) 50(42.0%) 69(58.0%) 89(74.8%) 30(25.2%)
Histological differentiation NS NS NS
pap 12(10.1%) 6(50.0%) 6(50.0%) 6(50.0%) 6(50.0%) 8(66.7%) 4(33.3%)
tub/well 20(16.8%) 9(45.0%) 11(55.0%) 6(30.0%) 14(70.0%) 16(80.0%) 4(20.0%)
tub/mod 40(33.6%) 17(42.5%) 23(57.5%) 17(42.5%) 23(57.5%) 32(80.0%) 8(20.0%)
tub/por 37(31.1%) 16(43.2%) 21(56.8%) 15(40.5%) 22(59.5%) 28(75.7%) 9(24.3%)
Adenoendocrine 1(0.8%) 1(100.0%) 0(0.0%) 0(0.0%) 1(100.0%) 0(0.0%) 1(100.0%)
Adenosquamous 7(5.9%) 3(42.9%) 4(57.1%) 5(71.4%) 2(28.6%) 5(71.4%) 2(28.6%)
Mucinous 2(1.7%) 0(0.0%) 2(100.0%) 1(50.0%) 1(50.0%) 0(0.0%) 2(100.0%)
Tumor invasion NS NS NS
Tis 5(4.2%) 2(40.0%) 3(60.0%) 2(40.0%) 3(60.0%) 4(80.0%) 1(20.0%)
T1 10(8.4%) 3(30.0%) 7(70.0%) 5(50.0%) 5(50.0%) 8(80.0%) 1(10.0%)
T2 41(34.5%) 21(51.2%) 20(48.8%) 16(39.0%) 25(61.0%) 35(85.4%) 6(14.6%)
T3 63(52.9%) 26(41.3%) 37(58.7%) 27(42.9%) 36(57.1%) 42(66.7%) 21(33.3%)
Stage NS NS *
0 5(4.2%) 2(40.0%) 3(60.0%) 2(40.0%) 3(60.0%) 4(80.0%) 1(20.0%)
I 9(7.6%) 3(33.3%) 6(66.7%) 5(55.6%) 4(44.4%) 8(88.9%) 1(11.1%)
II 23(19.3%) 9(39.1%) 14(60.9%) 7(30.4%) 16(69.6%) 20(87.0%) 3(13.0%)
III 19(16.0%) 12(63.2%) 7(36.8%) 8(42.1%) 11(57.9%)46. 15(78.9%) 4(21.1%)
IVA 63(52.9%) 26(41.3%) 37(58.7%) 28(44.4%) 35(55.6%) 42(66.7%) 21(33.3%)
Lymph node metastasis NS NS NS
Present 50(42.0%) 24(48.0%) 26(52.0%) 23(46.0%) 27(54.0%) 35(70.0%) 15(30.0%)
Absent 69(58.0%) 28(40.6%) 41(59.4%) 27(39.1%) 42(60.9%) 54(78.2%) 15(21.7%)
Lymphatic invasion NS NS NS
Present 107(89.9%) 46(43.0%) 61(57.0%) 45(42.1%) 62(57.9%) 79(77.6%) 24(22.4%)
Absent 12(10.1%) 6(50.0%) 6(50.0%) 5(41.7%) 7(58.3%) 10(83.3%) 2(16.7%)
Venous invasion NS NS NS
Present 74(62.2%) 33(44.6%) 41(55.4%) 35(47.3%) 39(52.7%) 55(74.3%) 19(25.7%)
Absent 45(37.8%) 19(42.2%) 26(57.8%) 15(33.3%) 30(66.7%) 34(75.6%) 11(24.4%)
Perineural invasion NS NS NS
Present 96(80.7%) 40(41.7%) 56(58.3%) 39(40.6%) 57(59.4%) 74(77.1%) 22(22.9%)
Absent 23(19.3%) 12(52.2%) 11(47.8%) 11(47.8%) 12(52.2%) 15(65.2%) 8(34.8%)
*;p<0.05, **;p<0.01, ***;p<0.0001, NS; not significant
pap; papillary adenocarcinoma, tub/well; tubular adenocarcinoma well differentiated type, tub/mod; tubular adenocacinoma moderately differentiated type , tub/por, tubula r
adenocarcinoma poorly differentia ted type, Adenoendocrine; Adenoendocrine carcinoma, Adenosquamous; Adenosquamous carcinoma, Mucinous;Mucinous adenocarcinoma
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ing for Ang-1, 2 and Tie-2, respectively (Table 1). Ang-1 and Ang-
2 were expressed in the cytoplasm of the carcinoma cells and Tie-2
was expressed in both membrane and cytoplasm of carcinoma cells
(Figure 1). In 38 cases of normal mucosa, 6 (15.8%), 10 (26.3%)
and 9 (23.7%) cases stained positively for Ang-1, 2 and Tie-2, re-
spectively. The positivity of staining for Ang-1 and Tie-2 in nor-
mal mucosa was significantly different from all carcinomas (p<0.01
and p<0.0001, respectively).
Expression of Ang-1, 2 and Tie-2 was variable in histological
types. Adenosquamous carcinomas showed relatively high expres-
sion of Ang-2 (71.4%) (Table 1). Tie-2 expression was relatively
high in all histological types of carcinomas except adenoendocrine
and mucinous carcinoma (Table 1). In no case, Ang-1, Ang-2 or
Tie-2 expression levels correlate with degree of histological differ-
entiation.
Expression of Tie-2 inversely correlated with the stage of tumor
invasion (p<0.05) (Table 1). There was also positive correlation
between Tie-2 expression and degree of desmoplastic stromal reac-
tion and tumor growth pattern (p<0.001 and p<0.05, respectively)
(Table 2). No significant correlations between expression of Ang-1
or Ang-2 and grade of tumor invasion, stage, stromal reaction or
tumor growth pattern were observed.
RT-PCR for Ang-1, 2 and Tie-2 in human bile duct carcinoma tis-
sues and cultured cell lines
Ang-1, 2 and Tie-2 cDNA was amplified from the total RNA of
all three cultured cell lines and all five tissues of human bile duct
carcinoma (Figure 2), but expression levels of Ang-1, 2 and Tie-2
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Table 2. Immunohistochemical staining for Ang-1, 2 and Tie-2 and the relationships between desmoplastic reaction and tumor growth pattern. (114 cases)
Ang-1 Ang-2 Tie-2
n + - + - + -
Total carcinoma 114 50(43.9%) 64(56.1%) 48(42.1%) 66(57.9%) 85(74.6%) 29(25.4%)
Desmoplastic stromal reaction NS NS **
Scirrhous 61(53.5%) 30(49.2%) 31(50.8%) 25(41.0%) 36(59.0%) 54(88.5%) 7(11.5%)
Non-scirrhous 53(46.5%) 20(37.7%) 33(62.3%) 23(43.4%) 30(56.6%) 31(58.5%) 22(41.5%)
Tumor growth pattern NS NS *
Infiltrative 74(64.9%) 36(48.6%) 38(51.4%) 31(41.9%) 43(58.1%) 60(81.1%) 14(18.9%)
Non-infiltrative 40(35.1%) 14(35.0%) 26(65.0%) 17(42.5%) 23(57.5%) 25(62.5%) 15(37.5%)
*; p<0.05, **; p<0.001, NS; not signif icant
Figure 1. Ang-1, 2 and Tie-2 immunoreactivity in the extrahepatic bile
duct carcinoma cells (A-C). Ang-1 and Ang-2 were expressed in the cyto-
plasm of carcinoma cell (A, B, respectively). Tie-2 was expressed in the
cellular membrane and the cytoplasm of carcinoma cell (C).
(Magnification; x400)
Figure 2. RT-PCR analysis of Ang-1, 2 and Tie-2 mRNA expression in
human bile duct carcinoma tissues and cultured cell lines. Total RNA tem-
plate was prepared from three cultured cell lines (Lane 1; HuCCT1, Lane
2; HuH28, Lane 3; OZ) and five human tissues of bile duct carcinoma
(Lanes 4-8). Size markers (Lane M) consist of 100-bp DNA ladder markers
(Invitrogen Corp.).
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mRNAs appeared to be vary among the samples. Amplification of
-actin cDNA was used to control for differences in loading, and
was detected in all samples.
Relationships between Ang-1, 2 and Tie-2 expression and the sur-
vival rates
Among the 119 cases, 54 cases were available for the investiga-
tion of their prognoses. The 5-year survival rate was 32.5%. A log-
rank test showed no statistical difference between Ang-1 or Ang-2
expression and survival rate (Figure 3 A, B), but there was a sig-
nificant difference between Tie-2 -positive or -negative cases and
survival among the patients of extrahepatic bile duct carcinoma
(p<0.05) (Figure 3C).
Discussion
Mechanisms regulating tumorigenesis and biological aggressive-
ness in extrahepatic bile duct carcinomas have not been clarified.
In the present study, we investigated the relationship between Ang-
1, 2 and Tie-2 expression in carcinoma cells and clinicopathological
factors of extrahepatic bile duct carcinoma using immunohistochemical
and molecular techniques. The data presented here provide some
evidence correlating Tie-2 expression with clinicopathological fac-
tors in bile duct carcinoma cells. Our results suggested the tumor
progression by autocrine/paracrine effects of Ang-1, 2 and Tie-2
expression in carcinoma cells.
Although previous study showed faintly expression of Ang-1, 2
and Tie-2 in normal mucosa of bile duct in the liver,36 we observed
Ang-1, 2 and Tie-2 expression in normal bile duct mucosa in this
study (Table 1). However, Ang-1 and Tie-2 expressions were in-
creased in carcinoma cells compared to normal mucosa, and the
difference was statistically significant (Table 1). Tie-2 expression
was very high among in total cancer samples (p<0.0001), 80.0%
of cases was Tie-2 positive in both Stage 0 and Tis grade. These
findings suggested that Tie-2 may play a progressive role in
carcinogenesis, and that Tie-2 expression could be a useful for dif-
ferential diagnosis between normal epithelial cell and carcinoma
cell of bile duct mucosa.
Factors that contribute to tumor angiogenesis play an important
role in tumor progression, in that angiogenesis is essential for the
nutrition, growth and metastasis of a tumor.37 Ang-1, a proangiogenic
protein, serves as a chemical signal for endothelial cells to induce
vascular maturation and stability during the angiogenesis.15 Positive
expression of Ang-1, 2 and Tie-2 in tumor cells has been demon
strated in gastric cancer,24 colorectal cancer,25 gastrointestinal stromal
tumors26 and glioma cells.27 Furthermore, there is a significant cor-
relation between a high degree of tumor vascularity, poor progno-
sis and low survival rates in cases of extrahepatic bile duct carci-
noma.38
Tie-2 expression was seen in carcinoma cells as well as stromal
fibroblasts. Almost all of carcinoma cells and stromal fibroblasts
expressed both Ang-1 and Ang-2 (data not shown). Previous stud-
ies have demonstrated that Ang-1 stimulates a Tie-2 dependent
pathway that modulates the activity of the cell-to-extracellular ma-
trix adhesion, and Ang-1 has also been reported to bind to Tie-2 di-
rectly as a binding protein itself.39-42 Other reports show that Ang-1
is only expressed in fibroblasts co-cultured with carcinoma cell
that express Ang-2, though neither the mono-cultured fibroblasts
nor the cancer cells expressed both Ang-1 and Ang-2.43 Ang-Tie
signaling has also been hypothesized to promote the growth of
both carcinoma cells and stromal fibroblast via direct cell interac-
tions.
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Figure 3. Kaplan-Meier survival curve after surgical therapy in patients of
bile duct carcinoma (54 cases). A log-rank test showed no statistical differ-
ence between Ang-1 or Ang-2 expression and survival rate (A, B, respec-
tively). Tie-2 positive patients had better prognosis (p<0.05, log-rank test)
(C).
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Data in this study showed a positive correlation between Tie-2
expression, tumor growth pattern and degree of desmoplastic stromal
reaction. Although our studies focused on autocrine/paracrine as-
pects of Ang-1, 2 and Tie-2 expression in carcinoma cells, we do
not argue that fibroblasts may also promote cancer progression.
Simultaneously, carcinoma cells could also promote fibroblast pro-
liferation via the same interactions. Such mechanisms may suggest
how the Ang-Tie pathway participates in the progression of
desmoplasia.
Our analysis detected a significant correlation between the ex-
pression of Tie-2 and a good prognosis for patients with bile duct
cancer (Figure 3C). Because Tie-2 expression was tend to be low
in deeper invasive cases, and later stage cases (Table 1), we hy-
pothesized that Tie-2 expression levels contribute to the good prog-
nosis of human malignancies. However, no examination of Tie-2 ex-
pression has been reported previously in any prognostic studies on
cancer, although some reports indicate that Ang-2 expression lev-
els are valuable for clinical prognosis.44-47 A positive correlation be-
tween Ang-2 expression in breast cancers and shorter disease-free
time and overall survival has been reported.44 Overexpression of
Ang-2 also associates with a significantly worse prognosis for pa-
tients with hepatocellular carcinoma, non-small cell lung carci-
noma or bladder cancer.45-47 However, tests of this study demon
strated no significant correlation between Ang-1 and Ang-2 expres-
sion and overall survival.
Gastrointestinal cancer, such as gastric or colorectal cancer, usu-
ally shows highly desmoplastic stromal reaction with deep inva-
sion of cancer cell. However, the cancer of extrahepatic bile duct
accompany desmoplasia in stroma and developes scirrhous feature
in early stage of tumor invasion.48 In our study, many cases (10 of
23, 43.5%) in stage II showed scirrhous feature, and desmoplastic
stromal reaction did not correlate with invasive grade. The correla-
tion between survivals of the patients and stromal reaction of the
extrahepatic bile duct cancer has been shown in recent report.49
However, both desmoplastic stromal reaction and tumor growth
pattern did not correlated with survivals of patients in this study
(data not shown).
Each clinicopathological factor; lymph node metastasis, lymph
duct invasion, venous invasion or perineural invasion, did not cor-
relate with the expression of Tie-2 in this study. However, the Tie-
2 expression was showed relatively higher in absence cases of
every factor except perineural invasion. The expression of Tie-2
significantly correlated with the grade of tumor stage that was di-
agnosed by the grade of tumor invasion and the presence of lymph
node metastasis and distant metastasis (p<0.01, table 1). And
tumor stage correlated with the prognosis of patients (p<0.0002,
data not shown). These results suggested that the expression of
Tie-2 may be an important factor in the tumor stage and prognosis.
We observed that Ang-1, 2 and Tie-2 were all highly expressed
in human extrahepatic bile duct carcinoma cells, and that there was
a significant correlation between Tie-2 expression and some
clinicopathological factors. These findings suggest that Ang-Tie
pathway plays a role in tumor progression and survival of patients
with bile duct carcinoma. Further studies are needed to clarify the
effect of Ang-Tie system on the prognosis of patients with bile
duct cancer.
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